CD123 + NKG2D

CD123 + NKG2D is a dual-target chimeric antigen receptor T cell (CAR-T) therapy designed to target both CD123 and ligands of the natural killer group 2 member D (NKG2D) receptor. This approach aims to improve efficacy in acute myeloid leukemia (AML), where tumor heterogeneity and an immunosuppressive microenvironment often limit the effectiveness of single-target CAR-T therapies. By simultaneously targeting CD123—commonly overexpressed on AML blasts and leukemia stem cells—and multiple NKG2D ligands present on AML cells as well as immunosuppressive myeloid-derived suppressor cells (M-MDSCs) and M2 macrophages, this dual-CAR strategy seeks to eradicate malignant cells while also depleting immunosuppressive elements that hinder immune response. The construct may include safety features such as a suicide gene for controlled elimination of infused cells[1][8]. Preclinical studies have demonstrated potent anti-leukemic activity and selective targeting of both tumor and suppressor cell populations[1][8].

Other names

CD123 + NKG2D 双靶点 CAR-T123NL CAR-T